Tracking outcomes after histotripsy for soft tissue tumors
Prospective Registry of Histotripsy for Soft Tissue Tumors
This registry collects information to see how safe and effective histotripsy is for adults treated for soft tissue tumors at UCSF.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT07470008 on ClinicalTrials.gov |
What this trial studies
This is a prospective observational registry enrolling adults who receive histotripsy as part of routine care at UCSF and following them for three years using information from their medical records. Tumor response will be measured on imaging using standardized criteria such as EASL, RECIST, and mRECIST, and clinical outcomes including progression-free and overall survival will be recorded. Adverse events will be captured and graded using the NCI CTCAE system to identify risk factors for complications. No experimental interventions are given as part of the registry; data are collected only from standard-care treatments and follow-up visits.
Who should consider this trial
Good fit: Adults who receive histotripsy as part of standard clinical care at UCSF and can provide consent are eligible for inclusion.
Not a fit: Children, adults lacking decision-making capacity, patients who do not consent, or people treated outside UCSF are not eligible and will not directly benefit from this registry's data collection.
Why it matters
Potential benefit: If successful, the registry could clarify how well histotripsy controls or shrinks soft tissue tumors and how safe it is, helping doctors and patients make informed treatment choices.
How similar studies have performed: Early clinical and preclinical reports of histotripsy have shown promising tumor ablation and safety signals, but prospective multicenter registries and long-term outcome data remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All adult patients who are treated with histotripsy per standard clinical care at University of California San Francisco (UCSF) are eligible for inclusion in the registry. Exclusion Criteria: * Children/minors, and adults who lack decision-making capacity, will be excluded from the registry. Patients who do not consent for inclusion in the registry will also be excluded.
Where this trial is running
San Francisco, California
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Ryan Lokken, MD — University of California, San Francisco
- Study coordinator: Ryan Lokken, MD
- Email: cancertrials@ucsf.edu
- Phone: 877-827-3222
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.